Gilead Sciences Inc. said that its Quad regimen for treating HIV infection met its primary objective in a Phase II study, fueling hopes that the combination pill could diversify the company's pipeline as its blockbuster HIV drugs face a looming patent cliff. (BioWorld Today)

Keryx, FDA Agree on Design of Phase III Zerenex Trials

Jan. 6, 2010

By Catherine Hollingsworth

Anesiva to Cease Operations After Merger with Arcion Dies

Jan. 5, 2010

By Catherine Hollingsworth

Tengion Joins Biotech IPO Parade Seeking Up to $40M

Dec. 28, 2009

By Catherine Hollingsworth

PTC Gets $50M to Launch Ataluren, Further Studies

Dec. 23, 2009

By Catherine Hollingsworth

PTC Therapeutics Inc. has completed a $50 million financing, the proceeds for which will be used to prepare for the anticipated launch of the drug in Duchenne's muscular dystrophy in the first half of 2011. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...